Literature DB >> 9054646

Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant.

J Nojima1, E Suehisa, N Akita, M Toku, R Fushimi, H Tada, H Kuratsune, T Machii, T Kitani, N Amino.   

Abstract

The relationship between arterial or venous thrombosis and the levels of anticardiolipin antibodies (aCL) and/or existence of lupus anticoagulant (LA) was studied. The 141 patients with systemic lupus erythematosus (SLE) were divided into four groups: aCL single positive (25 cases), LA single positive (11 cases), aCL and LA double positive (25 cases), aCL and LA double negative (80 cases). The prevalence of thrombosis was higher in aCL and LA double positive patients (21/25 cases, 84.0%, P <0.01) than that in aCL single positive patients (4/25 cases, 16.0%), LA single positive patients (1/11 cases, 9.1%) and double negative patients (3/80 cases, 3.8%). Furthermore, in these double positive patients, all patients (10/10 cases) with a high positive level of aCL (> 10 units/ml) had arterial thrombosis, whereas only 2/15 patients (13.3%) with a low positive level of aCL (3-10 units/ml) were affected. Venous thrombosis was frequently found in the low positive group (9/15 cases, 60.0%). On the contrary, none of 105 LA negative patients had arterial thrombosis and only seven (6.7%) had venous thrombosis. These findings indicate that a high aCL activity combined with a LA positive result might be a risk factor for arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054646     DOI: 10.1046/j.1365-2141.1997.d01-2055.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Real world experience with antiphospholipid antibody tests: how stable are results over time?

Authors:  D Erkan; W J M Derksen; V Kaplan; L Sammaritano; S S Pierangeli; R Roubey; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

2.  Multiple steno-obstructive vascular lesions and femoral superficial artery dissection in a young Caucasian male with antiphospholipid syndrome.

Authors:  Rosario Cianci; Antonietta Gigante; Biagio Barbano; Alvaro Zaccaria; Lelio Polidori; Francesca Borghesi; Ludovica Gasperini; Domenico Di Donato; Antonio Amoroso
Journal:  BMJ Case Rep       Date:  2009-05-12

3.  Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.

Authors:  N R Bijsterveld; S Middeldorp; F Berends; H R Büller
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study.

Authors:  Makiko Shibuya; Yukifumi Kimura; Shigeru Takuma; Nobuhito Kamekura Dds; Toshiaki Fujisawa
Journal:  Anesth Prog       Date:  2021-03-01

5.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

Review 6.  Screening for hypercoagulable syndromes following stroke.

Authors:  Cheryl Bushnell; Larry B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

Review 7.  VWF, Platelets and the Antiphospholipid Syndrome.

Authors:  Shengshi Huang; Marisa Ninivaggi; Walid Chayoua; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

8.  Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.

Authors:  Li Su; Zhigang Qi; Shaochen Guan; Lian Wei; Yi Zhao
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.